In a recent study, pemigatinib showed no difference in ORR, OS, and PFS between BICC1 and other partner genes, suggesting that FGFR2 inhibitors may be effective for cancer with FGFR2 fusion regardless of the partner gene [5]. This evidence concerns the gene BICC1 and cancer.